Protein Discovery Advances Alzheimer’s Biomarker Research

Research into Tau proteins is transforming Alzheimer's diagnostics, with plasma pTau181 and pTau217 biomarkers emerging as critical tools for early risk assessment.

Roche Diagnostics has developed the FDA-approved Elecsys pTau181 assay, which provides results in approximately 18 minutes with a 97.9% negative predictive value.

The SPEAR UltraDetect pTau217 assay has received FDA breakthrough device designation, offering high sensitivity for amyloid-PET positivity to support clinical trials and longitudinal studies.